文献速递甲状腺核医学肿瘤 PET/CT

18F-FCH PET/CT 在尿毒症性甲状旁腺功能亢进中的诊断价值

The role of 18F-FCH PET/CT in patients with uremic hyperparathyroidism compared with 99mTc-sestaMIBI SPECT/CT and ultrasonography.
PubMed 文献 · EJNMMI Res · 2019-12-26

该前瞻性研究纳入 17 例合并 5 期慢性肾脏病的尿毒症性甲状旁腺功能亢进(uHPT)患者,比较 18F-FCH PET/CT 与 99mTc-sestaMIBI SPECT/CT 及超声的诊断效能。共切除 63 个甲状旁腺增生病灶,18F-FCH PET/CT 检出 53 个且无假阳性,灵敏度和准确率高于另外两种方法。

要点

  • 18F-FCH PET/CT 对 uHPT 的灵敏度为 84.13%,准确率为 86.49%,均高于 SPECT/CT 和超声。
  • 18F-FCH PET/CT 阳性病灶的甲状旁腺体积显著大于阴性病灶(1.36±0.55 cm3 vs. 0.83±0.26 cm3,P=0.019)。
  • 超声将 3 例患者的甲状旁腺内增生误判为甲状腺结节,而 18F-FCH PET 正确识别了解剖位置。

核心结论

  • 18F-FCH PET/CT 对 uHPT 的灵敏度和准确率高于 99mTc-sestaMIBI SPECT/CT 和超声,术前诊断效能更优。

研究设计与样本

  • 前瞻性纳入 17 例合并 5 期慢性肾脏病的 uHPT 患者,均在 2 个月内完成超声、99mTc-sestaMIBI SPECT/CT 和 18F-FCH 检查并接受手术治疗。

主要发现

  • 17 例患者共切除 63 个甲状旁腺增生病灶,18F-FCH PET/CT 检出 53 个且无假阳性。
  • 18F-FCH PET/CT 的灵敏度、特异度、准确率、PPV、NPV 分别为 84.13%、100%、86.49%、100%、52.38%。
  • 99mTc-sestaMIBI SPECT/CT 的灵敏度、特异度、准确率、PPV、NPV 分别为 63.49%、90.91%、67.57%、97.56%、30.30%。
  • 超声的灵敏度、特异度、准确率、PPV、NPV 分别为 61.90%、81.82%、64.86%、95.12%、27.27%。
  • 18F-FCH PET/CT 阳性与阴性病灶的甲状旁腺体积差异有统计学意义(1.36±0.55 cm3 vs. 0.83±0.26 cm3,P=0.019)。

关键数值与推荐

  • 以术中定位和术后组织学结果为参考标准。
  • PET 参数与实验室参数之间无显著相关性。

临床怎么用

  • 对于 uHPT 患者,18F-FCH PET/CT 可作为术前定位的补充手段,尤其适用于超声误判为甲状腺结节的病灶。

局限性

  • 样本量较小(17 例患者,63 个病灶)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to evaluate the diagnostic efficacy of 18F-fluorocholine (18F-FCH) PET/CT for uremic hyperparathyroidism (uHPT) compared to 99mTc-sestaMIBI SPECT/CT and ultrasonography (US). METHODS: A total of 17 uHPT patients with stage 5 chronic kidney disease (CKD) were prospectively enrolled. All patients underwent US, 99mTc-sestaMIBI SPECT/CT, and 18F-FCH within 2 months and received surgical treatment. Visual and quantitative methods were used for image analyses. Intraoperative localization and postoperative histological results of the reference standard as well as the sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) of the three modalities were analyzed using Pearson's χ2 tests. In addition, the diagnostic efficacy of 18F-FCH PET/CT for uHPT was evaluated. The relationships between PET parameters and laboratory parameters were assessed using the Spearman correlation coefficient. RESULTS: A total of 63 parathyroid hyperplasia lesions were resected in 17 uHPT patients, and 53 lesions were detected using 18F-FCH PET/CT with no false-positive results. The sensitivity, specificity, accuracy, PPV, and NPV were 84.13%, 100%, 86.49%, 100%, and 52.38%, respectively. In comparison, the corresponding values for 99mTc-sestaMIBI SPECT/CT and US were 63.49%, 90.91%, 67.57%, 97.56%, and 30.30% and 61.90%, 81.82%, 64.86%, 95.12%, and 27.27%, respectively. The volume of hyper-functioning parathyroid glands was significantly different between lesions positive in 18F-FCH PET/CT and negative in 18F-FCH PET/CT (mean volume 1.36 ± 0.55 cm3 vs. 0.83 ± 0.26 cm3; P = 0.019). US misidentified intrathyroidal parathyroid hyperplasia as thyroid nodules in three patients, while 18F-FCH PET correctly identified the anatomy. No significant associations were observed between PET parameters and laboratory parameters in uHPT. CONCLUSION: 18F-FCH PET/CT was more sensitive and accurate for uHPT than 99mTc-sestaMIBI SPECT/CT and US, and had better preoperative diagnostic efficacy, particularly for lesions diagnosed as a thyroid nodule by US.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Xue Y, Li W, Xia Z, et al. The role of 18F-FCH PET/CT in patients with uremic hyperparathyroidism compared with 99mTc-sestaMIBI SPECT/CT and ultrasonography. EJNMMI Res. 2019. PMID: 31879808. doi:10.1186/s13550-019-0583-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。